-
Darunavir (known during development as TMC114 and given the proprietary name, PREZISTA-TM) was approved by FDA on June 23, 2006, for use in combination with other antiretroviral agents for the treatment of HIV infection in adults.
-
Lagrotteria and colleagues enrolled 39 inpatients with a primary episode of Clostridium difficile-associated diarrhea (CDAD) to receive treatment for 10 days with either metronidazole (MET) alone or together with rifampin (RIF).
-
This interesting paper from Groopman's laboratory at Beth Israel in Boston, reports the results of some elegant experiments designed to elucidate potential mechanisms, accounting for the innocent bystander hepatocyte apoptosis previously observed as a result of binding of HCV and HIV proteins.
-
The US Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents recommends efavirenz (EFV) as part of the preferred non-nucleoside reverse transcriptase inhibitor-based regimen for HIV patients.
-
TNF Blockers: Should You Be Concerned?; FDA Actions
-
It is widely accepted that vulnerable patients are best protected from acquiring invasive mold diseases by placing them in a protected environment, supplying sterile air by means of HEPA filtration with or without laminar air flow (LAF). However, there is little to support this contention.
-
The only manufacturer of VZIG in the United States recently stopped its production. An alternate product, VariZIG, which is manufactured by a Canadian company and has not been approved for use in the United States by the FDA, can be obtained in the United States, but only through expanded access as an investigational new drug.
-
What is the Best Way to 'Predict' Diabetes: IFG, IGT, or A1c?; Hair Growth With Finasteride: Not Just More, but More Better!; Prevalence of Diabetic Neuropathy; Hypogonadism is Surprisingly Common in Middle-Aged Men; Carpal Tunnel Syndrome: Capturing the Benefits of MultiModal Treatment; Diastolic Dysfunction: Not So Benign
-
Within the past few months, gatifloxacin (Tequin®) has received some attention in the medical community due to reports of serious hypoglycemia and hyperglycemia.
-
This paper presents the results of a retrospective cohort analysis from the Mayo Clinic of 79 patients with bacterial spine infection who underwent baseline and follow-up imaging studies with MRI.
